AstraZeneca halts studies on MEDI-578 product

LONDON, Dec 28 (BestGrowthStock) – British drugmaker AstraZeneca
(AZN.L: ) (AZN.N: ) has halted studies on MEDI-578, which treats
nerve growth, to assess data on the product further.

“We saw a reason to put a halt to the studies to evaluate
the data and ascertain a sensible path forward,” an AstraZeneca
spokeswoman said on Tuesday.

Several leading drug companies around the world have
suffered setbacks in plans to develop new products.

Earlier this month, AstraZeneca discontinued development of
experimental drug motavizumab and abandoned plans to develop an
experimental heart drug known as Certriad along with its
American partner Abbott Laboratories (ABT.N: ). [ID:nN22110750]
[ID:nLDE6BK07K]

Earlier this week, Regeneron Pharmaceuticals Inc (REGN.O: )
said U.S. regulators had placed the company’s experimental pain
drug for osteoarthritis on clinical hold after a patient in
another company’s trial developed a serious bone disorder.

Regeneron said it and partner Sanofi-Aventis SA (SASY.PA: )
were told late last week by the U.S. Food and Drug
Administration that the drug, REGN475/SAR164877, was being
placed on clinical hold after a patient in another company’s
trial developed avascular necrosis of a joint. [ID:nN27225337]
(Editing by Dan Lalor)

AstraZeneca halts studies on MEDI-578 product